VBLT Company Profile and Key Details
Vascular Biogenics Ltd.
VBLT Stock Price Chart
Stock Price Today
Vascular Biogenics Ltd. (VBLT) stock declined over -8.77%, trading at $0.16 on NASDAQ, down from the previous close of $0.17. The stock opened at $0.17, fluctuating between $0.15 and $0.19 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vessels; and monocyte targeting technology, an antibody-based technology that enables specifically inhibit monocyte migration for immune-inflammatory applications. The company's lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovarian cancer; and Phase II clinical trials treatment of recurrent glioblastoma and colorectal cancer, as well as has completed Phase II clinical trial for the treatment of thyroid cancer. It is also developing VB-601 for various inflammatory indications, and VB-611 for various solid tumors. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.
Company Information
| Employees | 7 |
| Beta | 0.71 |
| Sales or Revenue | $658.00K |
| 5Y Sales Change% | -1% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Vascular Biogenics Ltd. (NASDAQ: VBLT) stock price is $0.16 in the last trading session. During the trading session, VBLT stock reached the peak price of $0.19 while $0.15 was the lowest point it dropped to. The percentage change in VBLT stock occurred in the recent session was -8.77% while the dollar amount for the price change in VBLT stock was -$0.02.
The NASDAQ listed VBLT is part of Biotechnology industry that operates in the broader Healthcare sector. Vascular Biogenics Ltd. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Tami Rachmilewitz M.D.
Chief Medical Officer
Dr. Yael Cohen
Medical Director
Dr. Eyal Breitbart Ph.D.
Senior Vice President of Research & Operations
Dr. Erez Feige M.B.A., Ph.D.
Senior Vice President of Bus. Operations
Mr. Samuel Backenroth
Chief Financial Officer
Advocate Ayelet Horn
Gen. Counsel
Dr. Naamit Sher Ph.D.
Senior Vice President of Drug Devel. & Regulatory Affairs
Prof. Dror Harats M.D.
Chief Executive Officer & Director
Deborah Scott
Managing Director of Financial Communications
VBLT's closing price is 54.61% higher than its 52-week low of $0.10 where as its distance from 52-week high of $0.32 is -51.25%.
Number of VBLT employees currently stands at 7.
Official Website of VBLT is: https://www.vblrx.com
VBLT could be contacted at phone 972 899 35000 and can also be accessed through its website. VBLT operates from 8 HaSatat Street, Hevel Modi'in, 7178106, Israel.
VBLT stock volume for the day was 5.38M shares. The average number of VBLT shares traded daily for last 3 months was 787.72K.
The market value of VBLT currently stands at $12.11M with its latest stock price at $0.16 and 77.64M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com